NEWS & EVENTS

Catalent today welcomed the news that InterveXion has enrolled the first patient in STAMPOUT, the first trial in methamphetamine users of the first-in-class anti-methamphetamine antibody IXT-m200.

Catalent and Valerius Biopharma AG, a Swiss biopharmaceutical company, today announced that they are to collaborate on the development and manufacture of Valerius’ biosimilar products.

Catalent today announced that several of its formulation and manufacturing experts are to present and participate in the educational agenda at the INTERPHEX Conference and Exhibition, to be held the Javits Center.

Catalent today announced it has won ten categories in the annual CMO Leadership Awards. The Awards recognize top outsourcing partners, determined by feedback from sponsor companies who outsource manufacturing.

Catalent today announced that Mike Merges, Director of Strategic Growth of Biologics Analytical Services and Mike Sadick, Ph.D., Principal Scientist, Biologics Analytical Services, will be presenting at the upcoming CASSS WCBP Symposium.

Triphase Accelerator Corporation and Catalent today announced a presentation and publication relating to the preclinical development of TRPH-222, an anti-CD22 antibody-drug conjugate for the treatment of patients with lymphoma.

Catalent and Vaccinex today announced an agreement to develop an antibody-drug conjugate using Catalent’s proprietary SMARTag® and GPEx® technologies, and Vaccinex’s proprietary ActivMAb® technology.

Catalent today announced it has signed a multi-year agreement with Grid Therapeutics, LLC, for the development and manufacture of Grid’s lead therapeutic candidate for the treatment of solid tumors.

Catalent today announced it has completed the acquisition of Cook Pharmica LLC, an integrated provider of drug substance and drug product manufacturing and related services.